They found that treating AML and Acute Promyelocytic Leukemia (APL) cells with All-Trans Retinoic Acid (ATRA) inhibits Nrf2 and HO-1 function, thus, resulting in improved cell death [109]. The gene discussed is NFE2L2; the disease is acute myeloid leukemia.